春立醫療(01858.HK):2024年歸母淨利潤1.25億元 同比下降55.13%
格隆匯3月28日丨春立醫療(01858.HK)發佈公吿,截至2024年12月31日止年度,公司的營業收入為約人民幣8.06億元,較去年同期下降33.32%,主要是由於集採政策持續深化,公司對國家集中帶量採購政策積極貫徹執行,相關產品價格下降,毛利率下降。為應對行業政策的變化,保障集採中標產品的穩定供應,公司對集採實施前的渠道庫存進行價格調整,導致公司營業總收入減少。
2024年度,公司的毛利為約人民幣5.37億元,較去年同期下降38.70%,主要是由於受到國家高值耗材帶量採購落地實施的影響,公司相關產品售價下降所致。2024年度,公司研發費用為約人民幣1.33億元,較去年同期下降15.47%,主要是由於公司持續對研發費用投入,同時繼續對研發管理進行優化,提高研發效率和成果質量。
2024年度,公司實現歸屬於母公司股東的淨利潤約人民幣1.25億元,較去年同期下降55.13%,主要由於集採政策持續深化,公司對國家集中帶量採購政策積極貫徹執行,相關產品價格下降,毛利率下降。同時為應對行業政策的變化,保障集採中標產品的穩定供應,公司對集採實施前的渠道庫存進行價格調整,導致公司利潤減少。公司擬向全體股東每10股派發末期股息人民幣0.49元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.